NEUMORA THERAPEUTICS, INC. (NMRA) Current Ratio
- Current ratio · latest quarter: Value 4.50×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 4.50× | Current assets / current liabilities. $124.87M ÷ $27.78M ≈ 4.50× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 124.87M USD | Assets, Current |
| Current obligations | 27.78M USD | Liabilities, Current |
| Cash and equivalents | 116.83M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 4.15M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 60.00M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $124.87M | $27.78M | $116.83M | (m) | (m) | (m) | $4.15M | $60.00M | 4.50× |
| 2026-03-31 | $153.43M | $30.11M | $147.07M | (m) | (m) | (m) | $5.06M | $60.00M | 5.09× |
| 2025-12-31 | $190.54M | $32.45M | $182.53M | (m) | (m) | (m) | $3.38M | (m) | 5.87× |
| 2025-09-30 | $177.08M | $25.84M | $129.07M | $42.45M | (m) | (m) | $549.00K | $20.00M | 6.85× |
| 2025-06-30 | $222.91M | $21.16M | $124.52M | $93.06M | (m) | (m) | $644.00K | $20.00M | 10.54× |
| 2025-03-31 | $254.87M | $28.38M | $126.86M | $122.49M | (m) | (m) | $1.05M | (m) | 8.98× |
| 2024-12-31 | $314.06M | $29.89M | $142.15M | $165.43M | (m) | (m) | $3.31M | (m) | 10.51× |
| 2024-09-30 | $348.61M | $31.74M | $275.71M | $65.59M | (m) | (m) | $6.11M | (m) | 10.98× |
| 2024-06-30 | $398.32M | $23.13M | $150.68M | $220.96M | (m) | (m) | $1.08M | (m) | 17.22× |
| 2024-03-31 | $442.79M | $24.61M | $182.93M | $239.79M | (m) | (m) | $1.49M | (m) | 17.99× |
| 2023-12-31 | $478.28M | $25.11M | $374.04M | $79.94M | (m) | (m) | $337.00K | (m) | 19.05× |
| 2023-09-30 | $525.74M | $29.12M | $412.28M | $97.28M | (m) | (m) | $2.23M | (m) | 18.05× |
| 2022-12-31 | $387.95M | $23.70M | $240.94M | $130.94M | (m) | (m) | $7.15M | (m) | 16.37× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |